Muvon Therapeutics is developing an autologous cell therapy using patients' own muscle precursor cells (MPCs) to regenerate damaged sphincter and other skeletal muscle tissue, with electromagnetic stimulation supporting regeneration. The company's lead program targets stress urinary incontinence (SUI), initially focused on women, and is positioned as a minimally invasive, low‑risk therapy that uses no foreign materials. Preclinical work at the University of Zurich over 12 years showed nearly 90% recovery of original muscle strength six months after injection. Muvon began first‑in‑human studies (first patient treated March 2020) and the phase 1 study is proceeding toward finalization, with final results expected this autumn. The startup is a University of Zurich spin‑off, currently employs seven people, and has joined the Wyss Zurich incubator to support clinical development. Planned next steps include completing clinical studies and scaling up production by automating the manufacturing cycle to address a large patient population with SUI.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

May 2021